McKesson (NYSE:MCK – Get Free Report) and INVO Fertility (NASDAQ:IVF – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.
Profitability
This table compares McKesson and INVO Fertility’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| McKesson | 1.12% | -202.94% | 5.92% |
| INVO Fertility | -116.29% | -85.54% | -31.05% |
Risk & Volatility
McKesson has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, INVO Fertility has a beta of 2.42, suggesting that its stock price is 142% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for McKesson and INVO Fertility, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| McKesson | 0 | 4 | 15 | 0 | 2.79 |
| INVO Fertility | 1 | 0 | 0 | 1 | 2.50 |
McKesson presently has a consensus price target of $1,040.29, suggesting a potential downside of 3.84%. INVO Fertility has a consensus price target of $320.00, suggesting a potential upside of 12,160.54%. Given INVO Fertility’s higher possible upside, analysts plainly believe INVO Fertility is more favorable than McKesson.
Insider & Institutional Ownership
85.1% of McKesson shares are held by institutional investors. Comparatively, 12.0% of INVO Fertility shares are held by institutional investors. 0.1% of McKesson shares are held by company insiders. Comparatively, 0.4% of INVO Fertility shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares McKesson and INVO Fertility”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| McKesson | $403.43 billion | 0.31 | $4.76 billion | $38.89 | 27.82 |
| INVO Fertility | $6.84 million | 0.24 | -$25.13 million | ($135.32) | -0.02 |
McKesson has higher revenue and earnings than INVO Fertility. INVO Fertility is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks.
Summary
McKesson beats INVO Fertility on 10 of the 15 factors compared between the two stocks.
About McKesson
McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers. The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care. Founded in 1833, McKesson serves customers primarily in the United States and Canada.
About INVO Fertility
INVO Fertility, Inc. is a commercial-stage fertility company focused on expanding access to assisted reproductive technology. The company develops and commercializes fertility products and services designed to provide alternatives to conventional in vitro fertilization (IVF) treatment. Its principal product is INVOcell, a medical device used in the INVO Procedure. The system allows early-stage embryo incubation to take place inside the patient’s body rather than in a conventional laboratory incubator, while still involving the retrieval of eggs, fertilization, and subsequent embryo transfer under the supervision of fertility professionals.
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.
